ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009
From theoretical synergy to clinical supra-additive toxicity.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis.BJC reports · 2024Article
- Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- The renal damage and mechanisms relevant to antitumoral drugs.Frontiers in oncology · 2023Review
- Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer.Cancers · 2020Article
- CLytA-DAAO, Free and Immobilized in Magnetic Nanoparticles, induces Cell Death in Human Cancer Cells.Biomolecules · 2020Article
- Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.PloS one · 2019Article
- Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.JCO precision oncology · 2018Article
- Novel insights into mesothelioma biology and implications for therapy.Nature reviews. Cancer · 2017Review
- Combine and conquer: challenges for targeted therapy combinations in early phase trials.Nature reviews. Clinical oncology · 2017Review
- Sunitinib in the treatment of metastatic renal cell carcinoma.Therapeutic advances in urology · 2016Review
- Article
- Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma.Oncology reviews · 2016Review
- Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.Journal of the National Cancer Institute · 2016Review
- Anti-VEGF Cancer Therapy in Nephrology Practice.International journal of nephrology · 2014Review
- Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.Targeted oncology · 2012Review
- Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.Journal of cancer research and clinical oncology · 2012Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
19224836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.